

# Accepted Manuscript

Title: Virus Specific T Cells: Broadening Applicability

Author: A. John Barrett, Susan Prockop, Catherine M. Bollard

PII: S1083-8791(17)30759-0

DOI: <https://doi.org/doi:10.1016/j.bbmt.2017.10.004>

Reference: YBBMT 54814


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 3-10-2017

Accepted date: 3-10-2017

Please cite this article as: A. John Barrett, Susan Prockop, Catherine M. Bollard, Virus Specific T Cells: Broadening Applicability, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/doi:10.1016/j.bbmt.2017.10.004>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## VIRUS SPECIFIC T CELLS: BROADENING APPLICABILITY

A. John Barrett<sup>1</sup>, Susan Prockop<sup>2</sup>, Catherine M. Bollard<sup>3</sup>

1. Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, NIH, Bethesda MD

2. Memorial Sloan Kettering Cancer Center, New York, NY

3. Children's National and The George Washington University, Washington DC

Abstract: Virus infection still remains an appreciable cause of morbidity and mortality after Hematopoietic stem cell transplant (HSCT). While pharmacotherapy and/or antibody therapy may help to prevent or treat viral disease, these drugs are expensive, toxic and often ineffective due to primary or secondary resistance. Further, effective treatments are limited for many infections (e.g. Ad and BKV), which are increasingly detected after alternative donor transplants. These deficiencies in conventional therapeutics have increased interest in an immunotherapeutic approach to viral disorders, leading to adoptive transfer of virus-specific cytotoxic T lymphocytes (VSTs), which can rapidly reconstitute antiviral immunity post-transplant without causing GvHD. This review will explore how the VST field has improved outcomes for many patients with life threatening viral infections after HSCT and how to broaden applicability beyond the "patient specific" products as well as extending to other viral diseases even outside the context of HSCT.

**Keywords:** Adoptive T cell Therapy

Cytomegalovirus

BK virus

HIV

**INTRODUCTION**

Download English Version:

<https://daneshyari.com/en/article/8430480>

Download Persian Version:

<https://daneshyari.com/article/8430480>

[Daneshyari.com](https://daneshyari.com)